device development placed on hold

This study is being conducted to evaluate the ability of a light emitting diode (LED) study device's ability to raise the temperatures on flank tissue to a similar level compared to an approved laser device (SculpSure by Cynosure). Laser treatments have been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.

This is an open-label, feasibility study comparing the tissue temperature profile of a 950 nm LED device and a 1060 nm diode laser for non-invasive lipolysis of the flanks. The study will enroll up to 10 subjects requesting non-invasive lipolysis of the flanks. Each subject will receive a single treatment with each device on opposite flanks. Tissue temperatures in the treated areas will be recorded at various tissue depths and compared. Subjects will be asked to assess their discomfort and pain of the study treatment using a 10 cm visual analog scale (VAS). In addition, the safety (number of treatment related adverse events) of the LED device will be compared to the reference device at the time of treatment and one week later.

Inclusion Criteria:

• Healthy adult, male or female, ≥ 18 years of age or older with skin types 1-VI.
• Having moderate excess bilateral fatty tissue of the flanks, suitable area for non-invasive lipolysis.
• Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control for at least three months prior to enrolment and throughout the course of the study and have a negative urine pregnancy test at baseline.

Exclusion Criteria:

• Pregnant, expectation of pregnancy, postpartum or nursing (<6 months).
• History of skin disease in the area to be treated over the last 6 months.
• Previous surgical intervention to the treatment area.
• History of skin cancer or pre-cancerous lesions at the treatment areas.
• Having any electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
• History of immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications;
• Uncontrolled systemic diseases such as diabetes.
• Active infections in the treatment area.
• History of dysplastic nevi.
• Significant concurrent skin conditions or any inflammatory skin conditions.
• Active herpes simplex infections (e.g. cold sores), open lacerations or abrasions in the treatment area.
• Chronic or cutaneous viral, fungal, or bacterial diseases.
• Use of Accutane™ (Isotretinoin) within the past six months.
• Keloid or hypertrophic scar formation in the treatment area.
• Tattoos in the treatment area.
• History of auto-immune disorders.
• Erythema abigne, when identified treatments should be discontinued.
• History of photosensitivity disorder that can be exacerbated by laser or intense light.
• Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light.
• History of poor wound healing in the treatment area.
• Sunburns.
• Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a month) and during the course of the evaluation.
• Prior skin treatment with laser or other devices on the same treatment area within the last six months prior to study enrollment or during the course of the study.

This is a feasibility study. Sharing of IPD may occur if the study supports further development of the device.

Subject is receving LED treatment on the right abdomen and Laser treatment on the left abdomen.

The adverse events were collected from 7 June 2017 until 13 July 2017. All reportable events with start dates occurring any time after informed consent is obtained were followed until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation.